Chemocentryx Drug Patent Portfolio

Chemocentryx owns 1 orange book drug protected by 4 US patents Given below is the list of Chemocentryx's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11603356 Amorphous form of a complement component C5a receptor 29 May, 2041
Active
US11951214 Capsule formulations 27 Nov, 2039
Active
US8445515 C5aR antagonists 03 Feb, 2031
Active
US8906938 C5aR antagonists 21 Dec, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Chemocentryx.

Activity Date Patent Number
Patent litigations
Change in Power of Attorney (May Include Associate POA) 16 Apr, 2024 US11951214
Email Notification 16 Apr, 2024 US11951214
Change in Power of Attorney (May Include Associate POA) 12 Apr, 2024 US8906938
Change in Power of Attorney (May Include Associate POA) 12 Apr, 2024 US8445515
Email Notification 12 Apr, 2024 US8906938
Email Notification 12 Apr, 2024 US8445515
Patent Issue Date Used in PTA Calculation 09 Apr, 2024 US11951214
Recordation of Patent eGrant 09 Apr, 2024 US11951214
Email Notification 09 Apr, 2024 US11951214
Mail Patent eGrant Notification 09 Apr, 2024 US11951214
Recordation of Patent Grant Mailed 09 Apr, 2024 US11951214
Patent eGrant Notification 09 Apr, 2024 US11951214
Email Notification 03 Apr, 2024 US11603356
Change in Power of Attorney (May Include Associate POA) 03 Apr, 2024 US11603356
Email Notification 21 Mar, 2024 US11951214


Chemocentryx's Family Patents

Chemocentryx drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 24.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Chemocentryx Drug List

Given below is the complete list of Chemocentryx's drugs and the patents protecting them.


1. Tavneos

Tavneos is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11603356 Amorphous form of a complement component C5a receptor 29 May, 2041
(16 years from now)
Active
US11951214 Capsule formulations 27 Nov, 2039
(14 years from now)
Active
US8445515 C5aR antagonists 03 Feb, 2031
(6 years from now)
Active
US8906938 C5aR antagonists 21 Dec, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tavneos's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List